| [1］Jeromin S，Haferlach T，Grossmann V，et al.High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms［J］.Haematologica，2013，98(2)：e15-17. [2］Hata T，Miyazaki Y.The classification and therapy of myelodysplastic/myeloproliferative neoplasms(MDS/MPN)［J］.Nihon Rinsho，2012，70(Suppl 2)：342-346. [3］Medinger M，Skoda R，Gratwohl A，et al.Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms：correlation with clinical parameters and JAK2-V617F mutational status［J］.Br J Haematol，2009，146(2)：150-157. [4］Bejanyan N，Tiu RV，Raza A，et al.A phase 2 trial of combination therapy with thalidomide，arsenic trioxide，dexamethasone，and ascorbic acid(TADA)in patients with overlap myelodysplastic/myeloproliferative neoplasms(MDS/MPN)or primary myelofibrosis(PMF)［J］.Cancer，2012，118(16)：3968-3976. [5］张之南，沈悌.血液病诊断及疗效标准［M］.3版.北京：科学出版社：163-165. [6］Thapaliya P，Tefferi A，Pardanani A，et al.International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens［J］.Am J Hematol，2011，86(1)：96-98. |
